Cargando…

Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy

Detalles Bibliográficos
Autores principales:	Yalta, Kenan, Yetkın, Ertan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486848/ https://www.ncbi.nlm.nih.gov/pubmed/36148262 http://dx.doi.org/10.1016/j.cjco.2022.07.003

Ejemplares similares

Reply to Yalta and Yetkin—Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Duffett, Stephen A., et al.
Publicado: (2022)

Recurrent Cardiac Myxoma: A Puzzle to be Solved
por: Yalta, Kenan, et al.
Publicado: (2023)

Systemic Inflammation in the Setting of Cardiac Myxomas: an Overview of Clinical and Practical Considerations
por: Yalta, Kenan, et al.
Publicado: (2021)

Pheochromocytoma and Takotsubo Syndrome: An Ominous Duo
por: Yalta, Kenan, et al.
Publicado: (2022)

Evolving use and indications for implantable cardioverter defibrillators
por: de Groot, J. R.
Publicado: (2018)

Induced atrial fibrillation during defibrillation test on implantation of subcutaneous implantable cardioverter defibrillator
por: Kim, Ki-Hun, et al.
Publicado: (2020)

Takotsubo syndrome in the setting of COVID-19: Pathogenetic and diagnostic implications
por: Yalta, Kenan, et al.
Publicado: (2022)

Multisystem Inflammatory Syndrome Versus Kawasaki Disease: Potential Differences in Pathogenetic and Clinical Implications
por: Yalta, Kenan, et al.
Publicado: (2023)

Management of high-degree atrioventricular block in the setting of cardiac sarcoidosis: a therapeutic controversy
por: Yalta, Kenan, et al.
Publicado: (2022)

Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
por: Kempa, Maciej, et al.
Publicado: (2016)

Prognosis Determinants after Cardioverter-Defibrillators Implantation in Brazil
por: Migowski, Arn, et al.
Publicado: (2017)

Bridge to avoid ICD implantation with wearable cardioverter defibrillators
por: Zoppo, Franco, et al.
Publicado: (2020)

Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: a meta-analysis
por: Azoulay, Levi-Dan, et al.
Publicado: (2020)

Takotsubo syndrome in the absence of an overt stressor: A glimpse into its mechanistic and clinical aspects
por: Yalta, Kenan, et al.
Publicado: (2020)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Characteristics of Cardiac Memory in Patients with Implanted Cardioverter-defibrillators: The Cardiac Memory with Implantable Cardioverter-defibrillator (CAMI) Study
por: Haq, Kazi T., et al.
Publicado: (2021)

Obsessive-Compulsive Disorder as a Risk Factor in Patients with Implantable Cardioverter Defibrillator
por: Banihashemian, K, et al.
Publicado: (2011)

Fracture of DF-4 implantable cardioverter defibrillator lead in a pediatric patient
por: Dagriri, Khalid, et al.
Publicado: (2015)

To the Editor— Strategy for revision of subcutaneous implantable cardioverter-defibrillator following inappropriate shock
por: Winter, Joachim, et al.
Publicado: (2019)

Impact of implantable cardioverter defibrillator on survival in patients with non‐ischemic dilated cardiomyopathy
por: Kataoka, Naoya, et al.
Publicado: (2023)

Think twice before implanting leads in a swimmer: challenges in lead implantation of an implantable cardioverter-defibrillator
por: Varvarousis, Dimitrios, et al.
Publicado: (2021)

Incidence of Sudden Cardiac Death and Life-Threatening Arrhythmias in Clinically Manifest Cardiac Sarcoidosis With and Without Current Indications for an Implantable Cardioverter Defibrillator
por: Nordenswan, Hanna-Kaisa, et al.
Publicado: (2022)

Implantable cardioverter defibrillator therapy for secondary prevention in spontaneous coronary artery dissection: to place or not to place? This is the matter
por: Scagliola, Riccardo, et al.
Publicado: (2020)

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator
por: Skowasch, Dirk, et al.
Publicado: (2018)

Watchful Waiting in an Unusual Cause of Hypoxemia after Implantable Cardioverter-Defibrillator Lead Extraction
por: Bejko, Jonida, et al.
Publicado: (2019)

Letter to the Editor: Inappropriate subcutaneous implantable cardioverter‐defibrillator discharge related to myopotential oversensing
por: Chery, Godefroy, et al.
Publicado: (2020)

Reply to the Editor— Strategy for revision of subcutaneous implantable cardioverter-defibrillator following inappropriate shock
por: Do, Khuyen, et al.
Publicado: (2019)

Primary prevention implantable cardioverter–defibrillator therapy: a matter not yet adequately explored waiting for guidelines update
por: Guaricci, Andrea I., et al.
Publicado: (2017)

Implantable cardioverter-defibrillators /
Publicado: (1994)

First Experience of Cardiac Device Implantation with Remote Cardiac Support System in Turkey
por: Taylan, Gökay, et al.
Publicado: (2022)

Manual vs. automatic capture management in implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators
por: Murgatroyd, Francis D., et al.
Publicado: (2010)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy: a need or not?
por: de Groot, Joris R.
Publicado: (2023)

Implantation of Implantable Cardioverter Defibrillators in Kazakhstan
por: Begisbayev, Temirkhan, et al.
Publicado: (2022)

Prevention of sudden cardiac death by the wearable cardioverter defibrillator in a young patient with cardiac sarcoidosis
por: Andrié, René, et al.
Publicado: (2017)

Impairment of Quality of Life in Patients with Implanted Subcutaneous Cardioverter Defibrillator (S-ICD) Compared to Implanted Transvenous Cardioverter Defibrillator Therapy
por: Thienel, Manuela, et al.
Publicado: (2022)

The subcutaneous implantable cardioverter-defibrillator should be reserved for niche indications
por: Yang, Yang, et al.
Publicado: (2022)

Aortic aneurysm in patients undergoing transcatheter aortic valve implantation: A prognostic determinant? or just an innocent bystander?
por: Yalta, Kenan
Publicado: (2018)

The internal jugular vein as an alternative venous access for a revision of a fractured implantable cardioverter-defibrillator lead
por: Pae, Jong Yop, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio: A crucial determinant of reverse remodeling in patients with heart failure undergoing transcatheter aortic valve implantation?
por: Yalta, Kenan
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eugjdpkhfviun5fm430lrm4tka